Mode
Text Size
Log in / Sign up

PSMA PET/CT shows 95% specificity and 95% NPV for detecting lymph node invasionPET scans help identify lymph node involvement in prostate cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that PSMA PET/CT has high specificity and NPV for LNI, but limited sensitivity for detecting all metastatic nodes.

This meta-analysis evaluated the diagnostic performance of PSMA PET/CT for detecting lymph node invasion (LNI) in patients with intermediate-risk prostate cancer. The analysis included a total sample size of 1619 patients to determine the sensitivity, specificity, and negative predictive value (NPV) of the imaging modality.

The pooled results showed a sensitivity of 49% (95% CI 27-72%) for LNI. However, the specificity was reported at 95% (95% CI 93-97%), and the NPV was also reported at 95% (95% CI 91-98%). These findings suggest that while the test is highly specific for identifying positive nodes, its sensitivity is limited.

Authors noted limitations including moderate methodological quality of the included studies and the inherent risk of missing micrometastatic disease. Clinical application suggests that patients with intermediate-risk prostate cancer and a negative PSMA PET scan may potentially omit pelvic lymph node dissection at the time of radical prostatectomy. However, the clinical outcomes of omitting pelvic lymph node dissection are not established.

How this fits prior evidence

This meta-analysis extends the evidence regarding PSMA PET/CT in prostate cancer. It builds upon previous findings that PSMA PET/CT has higher sensitivity than mpMRI for detecting pelvic lymph node metastases, while noting that neither can exclude microscopic disease. This current study specifically quantifies the 95% specificity and 95% NPV for lymph node invasion in intermediate-risk patients.

When a patient is diagnosed with intermediate-risk prostate cancer, doctors must decide how to manage the spread of the disease. One key step is determining if the cancer has reached the lymph nodes. This information helps shape the surgical plan and the overall treatment path for the patient.

Researchers looked at data from 1,619 patients to see how well a specific type of imaging, called a PSMA PET scan, performs at finding this spread. The results showed that the scan is very specific, meaning it is highly accurate at confirming lymph node involvement when it is present. It also showed a high negative predictive value, which means it is very reliable at showing when lymph nodes are clear of cancer.

While the scan is reliable at confirming clear nodes, its sensitivity for finding every instance of spread was lower. Because of these mixed results and the risk of missing very small amounts of disease, the findings are still being weighed by experts. These results suggest that a clear scan might help doctors decide whether to skip certain lymph node removals during surgery, but this choice depends on the specific case.

What this means for you:
PSMA PET scans are highly reliable at confirming clear lymph nodes but may miss some small areas of cancer spread.

Common questions

How accurate is a PSMA PET scan at finding cancer in lymph nodes?

The scan showed a high specificity of 95% for finding lymph node involvement. This means it is very accurate at confirming when cancer is present. However, its sensitivity was lower at 49%, which means it may not catch every instance of cancer spread.

What does a negative predictive value of 95% mean for my scan?

A negative predictive value of 95% means that if your PSMA PET scan comes back clear, there is a very high probability that your lymph nodes are actually free of cancer. This helps doctors understand the likelihood of clear nodes before surgery.

Can this scan replace traditional methods for checking lymph nodes?

The data suggests that a clear scan might allow some patients to skip certain lymph node removals during surgery. However, because the scan has a lower sensitivity and can miss tiny amounts of disease, doctors must still weigh these results carefully for each individual patient.

Study Details

Study typeMeta analysis
Sample sizen = 1,619
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
OBJECTIVE: The aim of this study was to meta-analyze published data on the diagnostic performance of PSMA PET/CT in detecting lymph node invasion (LNI) in intermediate-risk prostate cancer (PCa) patients, and to discuss whether pelvic lymph node dissection (PLND) can be spared in patients with negative PSMA PET scan. PATIENTS AND METHODS: The PubMed and Embase databases were searched through November 2025 to identify relevant articles. Methodological quality of each study was assessed. Patient-based sensitivity and specificity were pooled using the bivariate random-effects model. Patient-based negative predictive value (NPV) was pooled using the DerSimonian-Laird model. Histopathology from PLND and clinical follow-up served as the reference standard. RESULTS: Twelve eligible studies, comprising a total of 1619 patients with intermediate-risk PCa, were included. Overall, the studies were of moderate methodological quality. The sensitivity and specificity of PSMA PET/CT for the detection of LNI ranged from 0% to 100% and from 87% to 99%, respectively, with pooled estimates of 49% [95% confidence interval (CI) 27-72%] and 95% (95% CI 93-97%), respectively. The NPV of PSMA PET/CT for the detection of LNI ranged from 74% to 100%, with pooled estimates of 95% (95% CI 91-98%). CONCLUSION: This meta-analysis of current diagnostic evidence suggests that intermediate-risk PCa patients with negative PSMA PET scan may omit PLND at the time of radical prostatectomy. However, the moderate sensitivity of PSMA PET and the associated risk of missing micrometastatic disease underscore the need for cautious application and shared decision-making. Further large-scale prospective validation studies and future follow-up results focusing on the clinical outcomes of these patients will lend stronger support to this approach.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.